(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Senmiao Technology Limited, Aprea Therapeutics, and Lumen Technologies.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Senmiao Technology Limited (AIHS) | 0.40 | 16.56% | 2023-12-12 10:23:07 |
| 2 | Aprea Therapeutics (APRE) | 3.99 | 14% | 2023-12-12 16:17:05 |
| 3 | Lumen Technologies (LUMN) | 1.54 | 12.04% | 2023-12-12 13:01:34 |
| 4 | ATA Creativity Global (AACG) | 0.90 | 11.22% | 2023-12-12 07:06:06 |
| 5 | ADiTx Therapeutics (ADTX) | 3.80 | 10.79% | 2023-12-12 07:44:05 |
| 6 | Incyte Corporation (INCY) | 62.09 | 8.85% | 2023-12-12 12:50:34 |
| 7 | ACM Research (ACMR) | 17.25 | 7.81% | 2023-12-12 07:17:06 |
| 8 | Wilhelmina International (WHLM) | 4.78 | 7.66% | 2023-12-12 01:42:06 |
| 9 | Akoustis Technologies (AKTS) | 0.57 | 7.48% | 2023-12-12 11:07:06 |
| 10 | Digital Turbine (APPS) | 6.53 | 7.13% | 2023-12-12 15:49:06 |
The three biggest losers today are Wheeler Real Estate Investment Trust, Clean Energy Fuels, and Wheeler Real Estate Investment Trust.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Wheeler Real Estate Investment Trust (WHLR) | 0.34 | -15.77% | 2023-12-12 01:43:06 |
| 2 | Clean Energy Fuels (CLNE) | 3.05 | -15.75% | 2023-12-12 12:26:19 |
| 3 | Wheeler Real Estate Investment Trust (WHLRP) | 1.30 | -14.47% | 2023-12-12 01:44:06 |
| 4 | Oracle (ORCL) | 101.73 | -11.64% | 2023-12-12 12:57:58 |
| 5 | Universal Stainless & Alloy Products (USAP) | 15.85 | -8.65% | 2023-12-11 19:44:05 |
| 6 | GoPro (GPRO) | 3.28 | -8.52% | 2023-12-12 12:27:46 |
| 7 | Adial Pharmaceuticals (ADIL) | 1.86 | -8.37% | 2023-12-12 07:41:08 |
| 8 | Adverum Biotechnologies (ADVM) | 0.83 | -7.68% | 2023-12-12 07:46:06 |
| 9 | Johnson Controls (JCI) | 52.34 | -7.48% | 2023-12-12 12:56:21 |
| 10 | Acutus Medical (AFIB) | 0.20 | -7.19% | 2023-12-12 08:23:07 |
Winners today
1. Senmiao Technology Limited (AIHS) – 16.56%
Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. Its services include the facilitation of automobile transaction and financing, connecting ride-hailing drivers to financial institutions to buy, or get financing on the purchase of, cars to be used to provide ride-hailing services. The company is also involved in the sale of automobiles; and provision of auto finance services. Senmiao Technology has strategic cooperation with Gaode Map for utilization in ride sharing initiatives. Senmiao Technology Limited was incorporated in 2017 and is based in Chengdu, the People's Republic of China.
NASDAQ ended the session with Senmiao Technology Limited jumping 16.56% to $0.40 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Senmiao Technology Limited has a trailing twelve months EPS of $-0.49.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.76%.
Volume
Today’s last reported volume for Senmiao Technology Limited is 33142 which is 42.88% above its average volume of 23195.
More news about Senmiao Technology Limited.
2. Aprea Therapeutics (APRE) – 14%
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
NASDAQ ended the session with Aprea Therapeutics jumping 14% to $3.99 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Aprea Therapeutics has a trailing twelve months EPS of $12.31.
PE Ratio
Aprea Therapeutics has a trailing twelve months price to earnings ratio of 0.32. Meaning, the purchaser of the share is investing $0.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.87%.
Moving Average
Aprea Therapeutics’s worth is under its 50-day moving average of $4.12 and higher than its 200-day moving average of $3.95.
Yearly Top and Bottom Value
Aprea Therapeutics’s stock is valued at $3.99 at 01:32 EST, way below its 52-week high of $12.00 and way higher than its 52-week low of $0.47.
Volume
Today’s last reported volume for Aprea Therapeutics is 21136 which is 111.12% above its average volume of 10011.
More news about Aprea Therapeutics.
3. Lumen Technologies (LUMN) – 12.04%
Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.
NYSE ended the session with Lumen Technologies rising 12.04% to $1.54 on Wednesday, after two sequential sessions in a row of losses. NYSE jumped 0.04% to $16,281.30, after three successive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-11.49.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -153.72%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Lumen Technologies’s EBITDA is 1.44.
Yearly Top and Bottom Value
Lumen Technologies’s stock is valued at $1.54 at 01:32 EST, way below its 52-week high of $6.09 and way higher than its 52-week low of $0.78.
Moving Average
Lumen Technologies’s worth is way higher than its 50-day moving average of $1.33 and way below its 200-day moving average of $1.91.
More news about Lumen Technologies.
4. ATA Creativity Global (AACG) – 11.22%
ATA Creativity Global, together with its subsidiaries, provides educational services to individual students through its training center network in China. The company's educational services include portfolio training, research-based learning, overseas study counselling, K-12 education assessment, and other educational services. It also offers online courses for students. The company was formerly known as ATA Inc. and changed its name to ATA Creativity Global in September 2019. ATA Creativity Global was founded in 1999 and is based in Beijing, China.
NASDAQ ended the session with ATA Creativity Global jumping 11.22% to $0.90 on Wednesday while NASDAQ rose 0.7% to $14,533.40.
Earnings Per Share
As for profitability, ATA Creativity Global has a trailing twelve months EPS of $-0.18.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.92%.
Volume
Today’s last reported volume for ATA Creativity Global is 7056 which is 40.92% above its average volume of 5007.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.1%, now sitting on 216.55M for the twelve trailing months.
Yearly Top and Bottom Value
ATA Creativity Global’s stock is valued at $0.90 at 01:32 EST, way below its 52-week high of $2.49 and way above its 52-week low of $0.80.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ATA Creativity Global’s EBITDA is 0.1.
More news about ATA Creativity Global.
5. ADiTx Therapeutics (ADTX) – 10.79%
ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
NASDAQ ended the session with ADiTx Therapeutics rising 10.79% to $3.80 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, ADiTx Therapeutics has a trailing twelve months EPS of $-12.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -698.6%.
Yearly Top and Bottom Value
ADiTx Therapeutics’s stock is valued at $3.80 at 01:32 EST, way below its 52-week high of $76.40 and way above its 52-week low of $3.27.
Revenue Growth
Year-on-year quarterly revenue growth declined by 61.5%, now sitting on 749.48k for the twelve trailing months.
Volume
Today’s last reported volume for ADiTx Therapeutics is 338097 which is 33.08% above its average volume of 254042.
More news about ADiTx Therapeutics.
6. Incyte Corporation (INCY) – 8.85%
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
NASDAQ ended the session with Incyte Corporation rising 8.85% to $62.09 on Wednesday, following the last session’s upward trend. NASDAQ rose 0.7% to $14,533.40, after three sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 33.03. Meaning, the purchaser of the share is investing $33.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 83.9% and 121.6%, respectively.
Volatility
Incyte Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.07%, a positive 0.22%, and a positive 1.20%.
Incyte Corporation’s highest amplitude of average volatility was 0.80% (last week), 1.14% (last month), and 1.20% (last quarter).
Moving Average
Incyte Corporation’s worth is way higher than its 50-day moving average of $55.07 and under its 200-day moving average of $63.64.
More news about Incyte Corporation.
7. ACM Research (ACMR) – 7.81%
ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide. It offers space alternated phase shift technology for flat and patterned wafer surfaces, which employs alternating phases of megasonic waves to deliver megasonic energy in a uniform manner on a microscopic level; timely energized bubble oscillation technology for patterned wafer surfaces at advanced process nodes, which provides cleaning for 2D and 3D patterned wafers with fine feature sizes; Tahoe technology for delivering cleaning performance using less sulfuric acid and hydrogen peroxide; and electro-chemical plating technology for advanced metal plating. The company markets and sells its products under the Ultra C brand name through direct sales force and third-party representatives. ACM Research, Inc. was incorporated in 1998 and is headquartered in Fremont, California.
NASDAQ ended the session with ACM Research jumping 7.81% to $17.25 on Wednesday, following the last session’s upward trend. NASDAQ jumped 0.7% to $14,533.40, after three sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, ACM Research has a trailing twelve months EPS of $1.08.
PE Ratio
ACM Research has a trailing twelve months price to earnings ratio of 15.97. Meaning, the purchaser of the share is investing $15.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.62%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26.1%, now sitting on 495.94M for the twelve trailing months.
Yearly Top and Bottom Value
ACM Research’s stock is valued at $17.25 at 01:32 EST, way under its 52-week high of $21.07 and way higher than its 52-week low of $6.91.
More news about ACM Research.
8. Wilhelmina International (WHLM) – 7.66%
Wilhelmina International, Inc. primarily engages in the fashion model management business. It specializes in the representation and management of models, entertainers, athletes, and other talent to various clients, including retailers, designers, advertising agencies, print and electronic media and catalog companies. The company offers fashion modeling talent and social media influencer services to clients, such as advertising agencies, branded consumer goods companies, fashion designers, Internet sites, retailers, department stores, product catalogs, and magazine publications. It is also involved in the licensing of the Wilhelmina name to third-parties, such as fashion model agencies; television syndication royalties and production series contracts; and celebrity management activities. The company has operations in Los Angeles, Miami, Chicago, and London, as well as a network of licensees in various local markets in the United States and internationally. Wilhelmina International, Inc. was founded in 1967 and is headquartered in Dallas, Texas.
NASDAQ ended the session with Wilhelmina International jumping 7.66% to $4.78 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.7% to $14,533.40, after three successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Wilhelmina International has a trailing twelve months EPS of $0.09.
PE Ratio
Wilhelmina International has a trailing twelve months price to earnings ratio of 53.11. Meaning, the purchaser of the share is investing $53.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2%.
More news about Wilhelmina International.
9. Akoustis Technologies (AKTS) – 7.48%
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
NASDAQ ended the session with Akoustis Technologies jumping 7.48% to $0.57 on Wednesday while NASDAQ rose 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Akoustis Technologies has a trailing twelve months EPS of $-0.95.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -83.63%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 5.3% and 25%, respectively.
Moving Average
Akoustis Technologies’s worth is way under its 50-day moving average of $0.64 and way under its 200-day moving average of $2.10.
Yearly Top and Bottom Value
Akoustis Technologies’s stock is valued at $0.57 at 01:32 EST, way under its 52-week high of $4.96 and way higher than its 52-week low of $0.46.
More news about Akoustis Technologies.
10. Digital Turbine (APPS) – 7.13%
Digital Turbine, Inc., through its subsidiaries, provides media and mobile communication products and solutions for mobile operators, application advertisers, publishers, device original equipment manufacturers (OEMs), and other third parties. Its application media software platform that enables mobile operators and OEMs to control, manage, and monetize devices. The company also provides programmatic advertising and targeted media delivery services; and other products and professional services directly related to the core platform. It operates in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, China, Mexico, Central America, and South America. The company is headquartered in Austin, Texas.
NASDAQ ended the session with Digital Turbine rising 7.13% to $6.53 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.7% to $14,533.40, after three sequential sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Digital Turbine has a trailing twelve months EPS of $-1.79.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.77%.
Volume
Today’s last reported volume for Digital Turbine is 7989370 which is 372.5% above its average volume of 1690850.
More news about Digital Turbine.
Losers Today
1. Wheeler Real Estate Investment Trust (WHLR) – -15.77%
Headquartered in Virginia Beach, VA, Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR ) is a fully integrated, self-managed commercial real estate investment company focused on owning and operating income-producing retail properties with a primary focus on grocery-anchored centers.
NASDAQ ended the session with Wheeler Real Estate Investment Trust sliding 15.77% to $0.34 on Wednesday, after two successive sessions in a row of losses. NASDAQ rose 0.7% to $14,533.40, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Wheeler Real Estate Investment Trust has a trailing twelve months EPS of $-48.39.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.88%.
Volume
Today’s last reported volume for Wheeler Real Estate Investment Trust is 1461040 which is 76.13% below its average volume of 6121550.
Yearly Top and Bottom Value
Wheeler Real Estate Investment Trust’s stock is valued at $0.34 at 01:32 EST, way below its 52-week high of $19.01 and way higher than its 52-week low of $0.16.
Revenue Growth
Year-on-year quarterly revenue growth grew by 34.7%, now sitting on 102.92M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Wheeler Real Estate Investment Trust’s EBITDA is 5.1.
More news about Wheeler Real Estate Investment Trust.
2. Clean Energy Fuels (CLNE) – -15.75%
Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. As of December 31, 2022, the company served approximately 1,000 fleet customers operating approximately 50,000 vehicles. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.
NASDAQ ended the session with Clean Energy Fuels dropping 15.75% to $3.05 on Wednesday, after three successive sessions in a row of gains. NASDAQ jumped 0.7% to $14,533.40, after three sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Clean Energy Fuels has a trailing twelve months EPS of $-0.41.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.21%.
Moving Average
Clean Energy Fuels’s value is way below its 50-day moving average of $3.62 and way under its 200-day moving average of $4.23.
Volume
Today’s last reported volume for Clean Energy Fuels is 3942380 which is 116.38% above its average volume of 1821970.
Revenue Growth
Year-on-year quarterly revenue growth declined by 24%, now sitting on 432.06M for the twelve trailing months.
More news about Clean Energy Fuels.
3. Wheeler Real Estate Investment Trust (WHLRP) – -14.47%
Headquartered in Virginia Beach, VA, Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR ) is a fully integrated, self-managed commercial real estate investment company focused on owning and operating income-producing retail properties with a primary focus on grocery-anchored centers.
NASDAQ ended the session with Wheeler Real Estate Investment Trust dropping 14.47% to $1.30 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Wheeler Real Estate Investment Trust has a trailing twelve months EPS of $-1.868.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.88%.
Moving Average
Wheeler Real Estate Investment Trust’s value is below its 50-day moving average of $1.42 and way below its 200-day moving average of $1.54.
Volume
Today’s last reported volume for Wheeler Real Estate Investment Trust is 15425 which is 112.75% above its average volume of 7250.
More news about Wheeler Real Estate Investment Trust.
4. Oracle (ORCL) – -11.64%
Oracle Corporation offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing. The company also offers cloud-based industry solutions for various industries; Oracle application licenses; and Oracle license support services. In addition, it provides cloud and license business' infrastructure technologies, such as the Oracle Database and MySQL Database; Java, a software development language; and middleware, including development tools and others. The company's cloud and license business' infrastructure technologies also comprise cloud-based compute, storage, and networking capabilities; and Oracle autonomous database, MySQL HeatWave, Internet-of-Things, digital assistant, and blockchain. Further, it provides hardware products and other hardware-related software offerings, including Oracle engineered systems, enterprise servers, storage solutions, industry-specific hardware, virtualization software, operating systems, management software, and related hardware services; and consulting and customer services. The company markets and sells its cloud, license, hardware, support, and services offerings directly to businesses in various industries, government agencies, and educational institutions, as well as through indirect channels. The company has a collaboration with Amdocs Limited to empower customers on their journey towards cloud and digital adoption. Oracle Corporation was founded in 1977 and is headquartered in Austin, Texas.
NYSE ended the session with Oracle sliding 11.64% to $101.73 on Wednesday while NYSE rose 0.04% to $16,281.30.
Earnings Per Share
As for profitability, Oracle has a trailing twelve months EPS of $3.37.
PE Ratio
Oracle has a trailing twelve months price to earnings ratio of 30.19. Meaning, the purchaser of the share is investing $30.19 for every dollar of annual earnings.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Oct 10, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 1.41%.
Previous days news about Oracle
- Oracle (orcl) Q2 earnings top estimates. According to Zacks on Monday, 11 December, "While Oracle has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Compared to estimates, oracle (orcl) Q2 earnings: A look at key metrics. According to Zacks on Monday, 11 December, "For the quarter ended November 2023, Oracle (ORCL Quick QuoteORCL – Free Report) reported revenue of $12.94 billion, up 5.4% over the same period last year. ", "Here is how Oracle performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Oracle.
5. Universal Stainless & Alloy Products (USAP) – -8.65%
Universal Stainless & Alloy Products, Inc., together with its subsidiaries, manufactures and markets semi-finished and finished specialty steel products in the United States and internationally. Its products include stainless steel, nickel alloys, tool steel, and various other alloyed steels. The company offers semi-finished and finished long products in the form of ingots, blooms, billets, and bars; flat rolled products, such as slabs and plates; and customized shapes primarily for original equipment manufacturers (OEMs), which are cold rolled from purchased coiled strip, flat bar, or extruded bar. Its semi-finished long products are primarily used to produce rods; and finished bar products that are principally used by OEMs and by service center customers for distribution to various end users. The company also offers conversion services on materials supplied by its customers. Its products are used in aerospace, power generation, oil and gas, heavy equipment, general, and automotive industries, as well as in the manufacturing of equipment for food handling, health and medical, chemical processing, and pollution control; and manufacturing of metals, plastics, paper and aluminum extrusions, pharmaceuticals, electronics, and optics. The company sells its products to service centers, forgers, rerollers, and OEMs. Universal Stainless & Alloy Products, Inc. was founded in 1994 and is headquartered in Bridgeville, Pennsylvania.
NASDAQ ended the session with Universal Stainless & Alloy Products sliding 8.65% to $15.85 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Universal Stainless & Alloy Products has a trailing twelve months EPS of $-0.16.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.63%.
Moving Average
Universal Stainless & Alloy Products’s worth is way above its 50-day moving average of $14.24 and way higher than its 200-day moving average of $12.37.
More news about Universal Stainless & Alloy Products.
6. GoPro (GPRO) – -8.52%
GoPro, Inc. develops and sells cameras, mountable and wearable accessories, and subscription services and software in the Americas, Europe, the Middle East, Africa, the Asia and Pacific region, and internationally. The company provides cloud connected HERO11 Black, HERO11 Black Mini, HERO10 Black, HERO10 Black Bones, HERO9 Black, and HERO8 Black waterproof cameras; MAX, a 360-degree waterproof camera; GoPro, a subscription service that includes full access to the Quik app, cloud storage supporting source video and photo quality, camera replacement, and damage protection; Quik subscription offers access to editing tools, which allows users to edit photos, videos, and create cinematic stories; and Quik app, a mobile app that enable users to get their favorite photos and videos with footage from any phone or camera. It also offers mounts and accessories comprising equipment-based mounts consisting of helmet, handlebar, roll bar, and tripod mounts that enable consumers to wear the mount on their bodies, such as wrist housings, magnetic swivel clips, chest harnesses, and head straps; media, display, and light mods; spare batteries, dive filters, and charging accessories and cables; and lifestyle gears. In addition, the company provides mobile and web applications that provides media workflow for archiving, editing, multi-clip story creation, and sharing content on the fly. GoPro, Inc. markets and sells its products through retailers and wholesale distributors, as well as through its GoPro.com website. The company was formerly known as Woodman Labs, Inc. and changed its name to GoPro, Inc. in February 2014. GoPro, Inc. was founded in 2002 and is headquartered in San Mateo, California.
NASDAQ ended the session with GoPro dropping 8.52% to $3.28 on Wednesday, after three successive sessions in a row of gains. NASDAQ jumped 0.7% to $14,533.40, after three sequential sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, GoPro has a trailing twelve months EPS of $-0.31.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.18%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GoPro’s stock is considered to be oversold (<=20).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 83.3% and positive 61.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
GoPro’s EBITDA is 0.45.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 1.03B for the twelve trailing months.
More news about GoPro.
7. Adial Pharmaceuticals (ADIL) – -8.37%
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
NASDAQ ended the session with Adial Pharmaceuticals sliding 8.37% to $1.86 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Adial Pharmaceuticals has a trailing twelve months EPS of $-8.98.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -247.34%.
Yearly Top and Bottom Value
Adial Pharmaceuticals’s stock is valued at $1.86 at 01:32 EST, way under its 52-week high of $15.00 and above its 52-week low of $1.77.
Volume
Today’s last reported volume for Adial Pharmaceuticals is 154767 which is 108.07% above its average volume of 74380.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 64% and 86.5%, respectively.
Moving Average
Adial Pharmaceuticals’s worth is way under its 50-day moving average of $2.30 and way under its 200-day moving average of $5.61.
More news about Adial Pharmaceuticals.
8. Adverum Biotechnologies (ADVM) – -7.68%
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
NASDAQ ended the session with Adverum Biotechnologies dropping 7.68% to $0.83 on Wednesday while NASDAQ jumped 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Adverum Biotechnologies has a trailing twelve months EPS of $-1.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.14%.
More news about Adverum Biotechnologies.
9. Johnson Controls (JCI) – -7.48%
Johnson Controls International plc, together with its subsidiaries, engages in engineering, manufacturing, commissioning, and retrofitting building products and systems in the United States, Europe, the Asia Pacific, and internationally. It operates in four segments: Building Solutions North America, Building Solutions EMEA/LA, Building Solutions Asia Pacific, and Global Products. The company designs, sells, installs, and services heating, ventilating, air conditioning, controls, building management, refrigeration, integrated electronic security, integrated fire detection and suppression systems, and fire protection and security products for commercial, industrial, retail, small business, institutional, and governmental customers. It also provides energy efficiency solutions and technical services, including inspection, scheduled maintenance, and repair and replacement of mechanical and control systems, as well as data-driven smart building solutions to non-residential building and industrial applications. In addition, the company offers control software and software services for residential and commercial applications. Johnson Controls International plc was incorporated in 1885 and is headquartered in Cork, Ireland.
NYSE ended the session with Johnson Controls falling 7.48% to $52.34 on Wednesday while NYSE jumped 0.04% to $16,281.30.
Earnings Per Share
As for profitability, Johnson Controls has a trailing twelve months EPS of $2.98.
PE Ratio
Johnson Controls has a trailing twelve months price to earnings ratio of 17.56. Meaning, the purchaser of the share is investing $17.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.07%.
Sales Growth
Johnson Controls’s sales growth for the current quarter is 5.5%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 14, 2023, the estimated forward annual dividend rate is 1.48 and the estimated forward annual dividend yield is 2.64%.
Previous days news about Johnson Controls
- Johnson controls (jci) lags Q4 earnings and revenue estimates. According to Zacks on Tuesday, 12 December, "While Johnson Controls has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Compared to estimates, johnson controls (jci) Q4 earnings: A look at key metrics. According to Zacks on Tuesday, 12 December, "For the quarter ended September 2023, Johnson Controls (JCI Quick QuoteJCI – Free Report) reported revenue of $6.91 billion, up 2.7% over the same period last year. ", "Here is how Johnson Controls performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Johnson Controls.
10. Acutus Medical (AFIB) – -7.19%
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.
NASDAQ ended the session with Acutus Medical sliding 7.19% to $0.20 on Wednesday while NASDAQ rose 0.7% to $14,533.40.
Earnings Per Share
As for profitability, Acutus Medical has a trailing twelve months EPS of $-1.12.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.28%.
Sales Growth
Acutus Medical’s sales growth is 33.6% for the current quarter and 63.3% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Acutus Medical’s EBITDA is 0.32.
Revenue Growth
Year-on-year quarterly revenue growth grew by 43.7%, now sitting on 19.66M for the twelve trailing months.
More news about Acutus Medical.
Stay up to date with our winners and losers daily report
